Cargando…
Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study
BACKGROUND: Type 1 retinopathy of prematurity (ROP) is occasionally observed in preterm infants after the postmenstrual age (PMA) of 40 weeks; however, evidence-based treatment guidelines are largely lacking. In this study, we report the clinical characteristics of preterm infants with type 1 ROP at...
Autores principales: | Lyu, Jiao, Zhang, Qi, Chen, Chunli, Xu, Yu, Ji, Xunda, Zhao, Peiquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390561/ https://www.ncbi.nlm.nih.gov/pubmed/30808338 http://dx.doi.org/10.1186/s12886-019-1067-4 |
Ejemplares similares
-
Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016) -
Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012) -
Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment
por: Gotz-Więckowska, Anna, et al.
Publicado: (2017) -
Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
por: Cao, Jing-Ke, et al.
Publicado: (2023) -
Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)